|Bid||1.2900 x 4000|
|Ask||1.3000 x 1800|
|Day's range||1.2200 - 1.3200|
|52-week range||0.4600 - 1.5200|
|Beta (5Y monthly)||2.72|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So take a moment...
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...